In patients diagnosed with myeloid leukaemia, who have exhausted immunity and naturally lack NKG2C+ NK cells, the NKG2C “engager” has the potential to generate a strong antitumor response against acute myeloid leukaemia blasts. Here, KLRC2 is linked to acute myeloid leukemia.